Business Wire

Belgravia Hartford Announces USD$5M Convertible Secured Debenture with Round13 DAF & Closing of C$4M Private Placement

16.7.2025 14:57:00 CEST | Business Wire | Press Release

Share

BELGRAVIA HARTFORD CAPITAL INC. (CSE:BLGV)(OTC:BLGVF)(FRA:ECA) ("Company" or “Belgravia”) is pleased to announce that:

  • it has entered into a binding agreement with Round13 Digital Asset Fund (“Round13 DAF”) for a secured convertible debenture for a one-time principal amount investment of USD$5,000,000 (the “Debenture”) convertible into common shares at C$0.71, being a 40% premium to the volume-weighted average trading price (the “VWAP”) for the seven consecutive days immediately preceding the date of this announcement; and
  • as a result of this above-market Debenture, Belgravia has elected to voluntarily reduce its non-brokered private placement to close on 16,091,822units (the “Units”) at a price of C$0.25 per Unit for aggregate gross proceeds of C$4,022,955.55(the “Offering”) to the Company.

New USD$5 Million Round13 DAF Debenture Convertible at C$0.71

The principal amount and interest of the Debenture is convertible into common shares of Belgravia at a conversion price (the “Conversion Price”) of C$0.71, being a 40% premium to the VWAP for the seven consecutive days immediately preceding the date of this announcement. In the case that, at any time prior to the maturity date of the Debenture, the VWAP of Belgravia common shares equals or exceeds C$1.42, being 200% of the Conversion Price for 20-consecutive trading days of the common shares on the Canadian Securities Exchange (the “CSE”), then 20% of the then-outstanding principal amount (together with a proportionate amount of accrued and unpaid interest) shall automatically convert into common shares of Belgravia without any further action of Round13 DAF. The Debenture bears interest at a rate of 4% per annum, accrued monthly, and matures two years from the closing date thereof.

Mehdi Azodi, CEO of Belgravia stated: “This continued support from Round13 DAF, our lead strategic advisor and partner in all areas of Bitcoin-related finance, results in any new securities issued being set at a 40% premium to the price of Belgravia shares for the seven consecutive days immediately preceding the date of the announcement – a far less dilutive mechanism for Belgravia to achieve its stated goals. In addition, as a result of this Debenture, Belgravia has determined that it is in the best interests of our shareholders, to voluntarily cap the Offering at slightly more than 40% of its initial size”.

Mehdi Azodi continued: “This path enables Belgravia to achieve an excess amount of additional Bitcoin than originally expected to our treasury but, most importantly, with almost 60% less dilution.”

Khaled Verjee, Managing Director of Round13 DAF added: “We are extremely pleased to continue to support our partners and believe Belgravia is building an innovative business where Bitcoin treasury strategies play an integral role. From its innovative capital structures, protecting shareholder value, to its suite of, soon to be launched, Bitcoin focused technical tools designed to increase shareholder value and growth at a BTC level, Belgravia is well-positioned in this space. For a microcap to be thinking the way Belgravia is, and to have the technical team it does, it is in our opinion a recipe for long term success”.

Closing of Offering

As disclosed by press release on June 24, 2025, the Company announced a non-brokered private placement of Units. Under the Offering, each Unit consists of one common share of the Company (a “CommonShare”) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”) at a price of C$0.25 per Unit. Each Warrant entitles the holder to acquire one additional Common Share at an exercise price of C$0.50 per share for a period of 12-months from the date of issuance. The Warrants will be subject to an acceleration clause whereby, if the closing price of the Common Shares on the CSE is greater than C$0.75 for a period of ten consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof. In such case, the Warrants will expire 30-days after the date of such notice. Under the Offering, a total of 16,091,822Units were issued at a price of C$0.25 per Unit for aggregate gross proceeds of C$4,022,955.55.

No finders fees or commissions were paid to any party in connection with either the Offering or the Debenture.

In accordance with the policies of the CSE and applicable securities legislation,the Common Shares and Warrants comprising the Units will be subject to a hold period of four months and one day from the date of issuance. In addition, closing of the Debenture is subject to all rules, policies and procedures of the CSE.

Belgravia intends to use the proceeds of the Debenture and the Offering to purchase Bitcoin, in line with the Company’s strategic objective of building a 100% Bitcoin only Treasury.

For more information, legal disclaimer and about Belgravia Hartford please visit, please visit www.belgraviahartford.com or www.blgvbtc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715265083/en/

Contacts

For More Information, Please Contact:

Mehdi Azodi, President & CEO
Belgravia Hartford Capital Inc.
(416) 779-3268
mazodi@blgv.ca

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye